In this second of a two-part podcast episode detailing new treatments for prostate cancer, Dr. Phillip Davis and Dr. Dan Stevens highlight the increasing accessibility of molecular imaging and radioligand therapy across the US and the potential for earlier use of these technologies. They also discuss the promise of future advancements including personalized cancer treatments, the use of new radioactive isotopes, and the integration of AI in imaging and workflows. Both doctors stress the rapid developments in prostate cancer detection and treatment, encouraging patients to stay informed and involved in their care.

Phillip Davis, MD, is a physician executive and new drug developer based in Charleston, South Carolina, with a background in general medicine and molecular imaging/nuclear medicine. Following completion of medical school and residency at the Medical University of South Carolina, he spent 10 years at the FDA in the Division of Medical Imaging and Radiation Medicine in Silver Spring, MD. He now leads US Clinical Development and supports Medical Affairs and New Asset Development at Blue Earth Diagnostics (BED), where he was the medical lead for a novel PET tracer approved by FDA in May of 2025.

Dan Stevens is a board certified (UK) pharmaceutical physician dedicated to translational science and drug development. He is a Fellow of the Faculty of Pharmaceutical Medicine at the Royal College of Physicians with a focus on novel oncology drug development and clinical development as they related to oncology and urology. Most recently, he has developed specific experience in targeted radioligand therapy.